Merck

John Gapper

This time last year, I wrote a New Year column with seven predictions for events that would occur in business in 2011. It is time for reckoning and I must say that I scored poorly, with only three out of seven correct.

To be fair to me, the predictions were deliberately provocative. As I noted at the time:  ”They are intended to be adventurous enough to be interesting – even if I turn out to be wrong, they should at least be things to watch.”

I was at least right about that. With no more excuses, let’s take a look at my predictions and what happened. Read more >>

Andrew Hill

Andrew Witty, GlaxoSmithKline’s chief executive, won plenty of column inches and airtime on Monday with the UK drug company’s offer to supply developing countries with millions of doses of its vaccine against rotavirus gastroenteritis, at a 95 per cent discount to the western market price.

Your first reaction might well be: if $2.50 a shot still covers GSK’s costs, Mr Witty’s making quite a margin on the $50 he charges the developed world for the drug. Read more >>